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A B S T R A C T
Regulation of vascular permeability plays a major role in the pathophysiology of visually threatening conditions
such as retinal vein occlusion and diabetic retinopathy. Principally, several factors such as vascular endothelial
growth factor (VEGF), are up-regulated or induced in response to hypoxia thus adversely aﬀecting the blood-
retinal barrier (BRB), resulting in retinal edema and neovascularisation. Furthermore, current evidence supports
a dysregulation of the inner retinal neural-vascular integrity as a critical factor driving retinal ganglion cell
(RGC) death and visual loss. The principal objective of this study was to interrogate whether Substance P (SP), a
constitutive neurotransmitter of amacrine and ganglion cells, may protect against N-methyl-D-aspartate (NMDA)-
induced excitotoxic apoptosis of ganglion cells and VEGF-induced vessel leakage in the retina. Tight junctional
protein expression and a Vascular Permeability Image Assay were used to determine vascular integrity in vitro.
The protective eﬀect of SP on RGC was established in ex vivo retinal explants and in vivo murine models. After
NMDA administration, a reduction in TUNEL+ cells and a maintained number of Brn-3a+ cells were found,
indicating an inhibition of RGC apoptosis mediated by SP. Additionally, SP maintained endothelial tight junc-
tions and decreased VEGF-induced vascular permeability. In conclusion, administration of SP protects against
NMDA apoptosis of RGC and VEGF-induced endothelial barrier breakdown.
1. Introduction
The retina is one of the most metabolically active tissues and its
demand for oxygen is higher than many other tissues including the
brain [1,2]. Optimal function of the retina is dependent on a continuous
supply of oxygen from the circulation [3]. A number of retinal disorders
are propagated as a result of loss of retinal vascular integrity and sub-
sequent retinal cell apoptosis. For example, in conditions such as retinal
artery or vein occlusions and diabetic retinopathy, ischemia causes an
up-regulation hypoxia-inducible factors such as HIF-1 alpha which
elevate pro-angiogenic factors including vascular endothelial growth
factor (VEGF). As a result the blood-retinal barrier (BRB) is disrupted
which leads to increased vascular permeability. With respect to the
inner retinal barrier the resulting leakage of ﬂuid into the inner retina is
a critical response implicated in retinal ganglion cell (RGC) death and
loss of vision [4]. RGC are integral to processing of visual information
and thus critical for vision [5]. Due to RGCs and other central nervous
system neurons failure to regenerate after injury, the loss of RGCs ob-
served in many retinal diseases further contribute to visual loss [6].
Chronic diseases such as glaucoma and diabetic retinopathy are asso-
ciated with RGC death [7,8] and associated with persistent ischemia in
glaucoma [9,10], either by mechanical compression of retinal blood
vessels around the optic nerve head caused by increased intraocular
pressure or by ineﬀective vascular autoregulation [11]. The implication
is that additional therapeutic options should be considered addressing
the retinal neurovascular unit [12]. Consequently, therapeutic strate-
gies for enhancing RGC viability (neuroprotection) and preventing or
reversing retinal neuronal dysfunction as well as vascular leakage re-
main a goal of basic and translational research.
Substance P (SP) is a neuropeptide secreted by neurons and is in-
volved in many biological processes via speciﬁc receptors [13]. More
than 10 neuropeptides are expressed in the inner nuclear layer and the
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ganglion cell layer of the retina, of which SP is the most abundant
[14,15,16]. SP modulates a diverse set of pathways, including those
involved in vasodilatation, cell proliferation, apoptosis, and in-
ﬂammation [17], as well as promoting the migration and diﬀerentiation
of vascular endothelial cells [18]. Animal models have provided in-
sights into the biology of this peptide, and compelling evidence high-
lights the importance of SP in cell-to-cell communication by either
paracrine or endocrine signaling [13]. Moreover, higher levels of SP are
observed in retina in response to acute stress [19]. A corollary observed
is that SP is markedly reduced in diabetes [20,21], supporting a notion
that SP may be important for the retinal health and its loss contributes
to disease progression.
Based on these functions, we hypothesized that SP is neuroprotec-
tive, attenuating retinal neural apoptosis and maintains inner retinal
vascular integrity. In this study, the eﬀect of SP was assessed by eval-
uating endothelial and ganglion cell viability, apoptosis, and vascular
permeability. ex vivo, as well as in an animal model in vivo.
2. Materials and methods
2.1. Intravitreal administration of VEGF and N-methyl-D-aspartate
(NMDA)
All procedures were conducted under the regulation of the United
Kingdom Home Oﬃce Animals (Scientiﬁc Procedures) Act 1986, and
were in compliance with the Association for Research in Vision and
Ophthalmology (ARVO) statement for the use of animals in ophthalmic
and vision research. The methods were carried out in accordance with
the approved University of Bristol institutional guidelines and all ex-
perimental protocols under Home Oﬃce Project Licence 30/3045 and
30/3281 were approved by the University of Bristol Ethical Review
Group.
In vivo retinal vascular permeability was assessed as previously
described [22]. Eight-week-old C57BL/6 mice were purchased from
Charles River. Brieﬂy, adult mice were deeply anesthetized by in-
traperitoneal injection of Vetelar (ketamine hydrochloride 100mg/ml,
Pﬁzer, UK) and Rompun (xylazine hydrochloride 20mg/mL, Bayer, UK)
mixed with sterile water in the ratio 0.6:1:84, and the pupils of mice
were dilated using topical 1% tropicamide (0.5% w/v, Bausch & Lomb,
Aubenas, France), before induction of anesthesia. Mice received the
following intravitreal injections (2 μl) with a 33-gauge needle into one
eye: VEGF (v7259, Sigma-Aldrich, in distilled water) (100 ng); SP
(ab120170, Abcam, in distilled water) (20 nmol); VEGF plus SP to-
gether; 0.9% saline vehicle. 48 h post the ﬁrst injection mice received
tail vein injections of Evans Blue (200 μl, 2%). Mice were killed 10min
later and eyes were ﬁxed with 4% paraformaldehyde (PFA) for 2 h.
Retinal ﬂatmounts were mounted in antifading medium (Vector La-
boratories, Inc., Burlingame, CA, UAS), and images were captured by
Leica SP5-AOBS confocal laser microscope.
NMDA (M3262, Sigma-Aldrich, in distilled water) was used to in-
duce excitotoxicity of RGC in the retina, under experimental conditions
described above. Mice received the following intravitreal injections
(2 μl) with a 33-gauge needle into one eye: NMDA (10 nmol); SP
(20 nmol); NMDA with SP together; 0.9% saline vehicle control. Mice
were killed 24 h following NMDA injection, and retinal ﬂatmounts from
eyes prepared. Eyes were ﬁxed in 2% PFA for 2 h for TUNEL labeling as
well as immunoﬂuorescence staining.
2.2. Retinal explant culture ex vivo model
Retinal explant culture was performed as per protocol [23], Han
Wistar rat (20-old-day) with healthy, untreated eyes were killed by
exposure to a rising concentration of carbon dioxide followed by cer-
vical dislocation. The retina was dissected radially into four equal-sized
pieces, and individual explants positioned onto 12-mm diameter ﬁlters
(0.4 μm pore, Millipore) with the RGC side facing up. The ﬁlters were
placed into the wells of a 24-well plate, each of which contained 800 μl
of retinal explant media, consisting of neuronal growth medium
(Neurobasal A) supplemented with 2% B27 (Invitrogen Ltd.), 1% N2
(Invitrogen Ltd.), L-glutamine (0.8 mM), penicillin (100 U/ml) and
streptomycin (100 μg/ml). Retinal explant cultures were maintained in
humidiﬁed incubators at 37 °C and 5% CO2. Half of the media were
changed on day 1 and every second day thereafter.
2.3. Cell culture and viability
Mouse Primary Retinal Microvascular Endothelial cells (MRMECs,
Generon, UK) were cultured in Complete Mouse Endothelial Cell
Medium (Generon, UK). Cell viability was assessed using the MTT
assay. A total of 2×104 cells were seeded in each well of a 48-well
plate and cultured for 48 h to conﬂuency. Following serum starvation
for 24 h, fresh medium supplemented with diﬀerent concentrations of
VEGF (25–200 ng/ml) or SP (1–80 μM) were added for a further 24 h.
To assess cell viability, the MTT assay was performed according to
manufacturer's instructions. In brief, 50 μl of MTT solution (Thermo
Fisher Scientiﬁc, UK) was added to each culture well, and the plate was
incubated for a further 2 h at 37 °C with 5% CO2. The MTT solution was
replaced with HCl/isopropyl alcohol to dissolve formazan, and the
optical density (OD) of the wells was measured at 562 nm on a mi-
croplate reader and was calculated using linear regression analysis.
2.4. In vitro vascular permeability assay
Permeability visualization experiments were performed using
18× 18mm glass coverslips coated with biotinylated gelatin and
placed in 35mm culture dishes. MRMECs were seeded (4.5× 105 cells/
dish) and cultured for 72 h to reach 100% conﬂuency. Culture medium
was changed to serum free medium supplemented with treatment
(VEGF, SP or SP+VEGF) for a further 24 h. To evaluate permeability of
the MRMEC monolayer, Fluorescein conjugated streptavidin (25 μg/ml
ﬁnal concentration) was directly added to the culture medium for
5 min, washed twice with PBS, before cell ﬁxation with 3.7% for-
maldehyde in PBS 10 min, room temperature (RT). Overlay of
Fluorescein and Zonula occludens-1 (ZO-1) staining demonstrates re-
ciprocal relations between ZO-1 peripheral localization and increased
local permeability of Fluorescein-streptavidin. The pattern of
Fluorescein-streptavidin binding to the biotinylated gelatin underlying
the cell monolayer was examined under Leica SP5-AOBS confocal laser
microscope. Images were processed with ImageJ software. The per-
centage expression of ﬂuorescein intensity was taken from areas with
associated DAPI staining only, therefore excluding non-cellular area of
ﬂuorescence.
2.5. Immunoﬂuorescence staining
Rat retinal explants were ﬁxed with 4% PFA and plus 4% sucrose
and snap frozen in OCT (VWR Chemicals, UK). Cryosections were
prepared, washed in PBS and permeabilized with 0.1% Triton X-100.
Non-speciﬁc staining was blocked with 5% BSA in PBS for 30min at RT
followed by immunostaining with goat anti-mouse GFAP (Cell Signaling
Technology, UK, 1:100), rabbit anti-mouse Brn-3a (Santa Cruz
Biotechnology, Inc., UK, 1:50), goat anti-mouse Rhodopsin (Abcam,
UK, 1:100) antibodies. The secondary antibodies Alexa Fluor 549-la-
beled donkey anti-goat IgG (Invitrogen, CA) and Alexa Fluor 488-la-
beled donkey anti-rabbit IgG (Invitrogen, CA), both with 1:200 dilution
in 2% BSA in PBS at room temperature (RT) for 1 h in the dark.
Exclusion of the primary antibody acted as the negative control.
2.6. TUNEL assay
The terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay was performed according to the instructions provided by
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the manufacturer (Roche; Indianapolis, IN). In brief, ﬁxed retinal ex-
plant were washed in PBS, retinas were incubated in 0.1% Triton X-100
for 1 h to permeabilize the cells, rinsed three times with PBS, before
incubation with the TUNEL reaction mixture for 1 h at 37 °C. Retina
were mounted using anti-fading mounting medium (Vector
Laboratories, Inc., Burlingame, CA), and apoptotic cells were observed
using Leica SP5-AOBS confocal laser microscope. The number of TUNEL
+ cells in retinal explant was counted in ﬁve random ﬁelds on each
retinal explant (four per condition), and the average number of TUNEL
+ cells per random ﬁeld was determined for each condition tested. In
vivo TUNEL staining was quantitatively analyzed by determining the
intensities of TUNEL+ cells from dissected whole retina tissues (n = 6
per group) using ImageJ.
2.7. Retinal ﬂatmount
The whole retina was carefully dissected from the eyecup, per-
meabilized with 0.2% Triton X-100 and non-speciﬁc binding blocked by
5% normal goat serum in PBS for 2 h RT. The retinas were then
incubated with the primary antibody (puriﬁed rabbit anti-Brn-3a
(1:100)) for 24 h at 4 °C. Tissues were washed before incubation with
secondary Cy3 conjugated goat anti-rabbit IgG (1:250) for 2 h at RT.
For TUNEL staining, retinas were incubated with the reaction mixture
for 2 h at 37 °C, before being ﬂat mounted onto microscope slides and
covered with anti-fading mounting medium for confocal microscopy.
The number of Brn-3a+ cell bodies was determined from four separate
ﬁelds of view (the same distance from the optic nerve) per retinal
ﬂatmount and expressed as an average number of Brn-3a+ cells per
ﬁeld.
2.8. SDS-PAGE analysis
Cultured MRMEC cells were washed twice with ice-cold PBS before
lysis with ice-cold CelLytic™ MT Cell Lysis Reagent (Sigma-Aldrich,
UK). Cell lysates were centrifuged at 14,000 g for 10min at 4 °C, the
supernatant was transferred to fresh tubes and protein concentration of
samples determined using a Pierce BCA Protein Assay Kit (Thermo
Fisher Scientiﬁc, UK). Equal amounts of protein were mixed with 4x
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Fig. 1. Eﬀects of Substance P on the expression of tight junction protein ZO-1 in MRMEC cells. (A, B) Cells were deprived of serum for 24 h and then incubated in the
presence of SP or VEGF. MRMEC viability was determined in each group using the MTT assay. Data were normalized by control. (C, D) ZO-1 expression in MRMECs
deprived of serum for 24 h, upon treatment with SP (0–40 μM) or VEGF (0–200 ng/ml). (E) ZO-1 expression in MRMECs deprived of serum for 24 h and then
incubated in the presence of SP (20 μM), VEGF (100 ng/ml) or SP with VEGF (pre-incubated with SP for 6 h before addition of VEGF). (F, G) p44/p42 MAPK, p38
MAPK and ZO-1 expression in MRMECs treated with SP (20 μM) or VEGF (100 ng/ml). Data represents means ± SD of relative values vs control from 3 independent
experiments. *P < 0.05; ***P < 0.001, statistical analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons.
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SDS sample buﬀer, boiled for 10min at 90 °C, and resolved using
4%–20% NuPAGE gels (Invitrogen, UK). Proteins were transferred to
PVDF membranes (Invitrogen, UK), blocked with 5% skimmed milk for
2 h, and incubated overnight at 4 °C with primary antibodies: Anti-ZO-1
(Merck, UK; 1: 1000), anti-p38 MAPK (Cell Signaling Technology, UK;
1: 1000), anti-p44/42 MAPK (Cell Signaling Technology, UK; 1: 1000)
and β-actin (Cell Signaling Technology, UK; 1:1000). Excess antibody
was removed by washing the membrane in PBS/0.1% Tween 20, and
the membranes were incubated for 2 h with horseradish peroxidase-
conjugated secondary antibodies (Abcam, UK; 1:2000). Following fur-
ther washes in PBS/0.1% Tween 20, the signals were developed with
ECL reagent (Sigma, UK) and captured by an electronic imaging system
(Konica Minolta). Restore™ PLUS Western Blot Stripping Buﬀer
(Thermo Fisher Scientiﬁc, UK) was used to re-blot the membranes. The
density of protein was quantiﬁed using the ImageJ.
2.9. Statistics
All experiments were repeated at least three times. Results are
therefore presented as means ± standard deviation (S.D.).
Comparisons of two individual experimental groups were performed by
unpaired Student's t-test and Mann-Whitney test. For multiple com-
parisons, nonparametric analysis was performed using one-way ANOVA
test with Dunn's test. All the analysis was performed using GraphPad
Prism 6 (GraphPad Software, version 6.01, La Jolla, USA). Two-tailed
tests were used throughout. The signiﬁcant diﬀerences were considered
at P≤ 0.05.
3. Results
3.1. SP regulates ZO-1 expression in cultured MRMECs, through MAP-
kinase inactivation.
Toward initial understanding of role of SP in regulation of vascular
barriers we examined the eﬀects of SP on the tight junction proteins in
primary retinal microvascular endothelial cells (MRMECs). We assessed
the response of MRMECs following exposure to VEGF, SP or a combi-
nation of VEGF and SP. At all concentrations tested, VEGF had no eﬀect
on cell viability, while we established that SP demonstrated toxicity at
the high dose of 80 (μM) in vitro (Fig. 1A–B), which we therefore
omitted from further experiments. VEGF resulted in a dose-dependent
reduction of ZO-1 in MRMECs as shown by Western blot, whereas SP at
non-toxic doses increased signiﬁcantly ZO-1 expression in a dose-de-
pendent manner (Fig. 1C–D). Treatment of cultured MRMECs with
VEGF led to a signiﬁcant (52%) reduction of ZO-1 expression as com-
pared to untreated control. Incubation of the cells with SP (20 μM),
applied 6 h before VEGF treatment, showed an increase in ZO-1 ex-
pression by 43% compared to VEGF alone. (Fig. 1E).
To understand the potential mechanism for the observed SP pro-
tective eﬀect, we examined expression of MAP-kinase which is re-
cognised to modulate the cellular expression of tight junction proteins
in response to various stimuli [24]. In MRMECs, we showed that SP
treatment signiﬁcantly reduced the phosphorylated forms, p38-MAPK
and p44/p42 MAPK. The data supported that treatment of MRMECs
with SP led to down-regulation of activated MAPK isoforms, accom-
panied by increased expression of ZO-1, compared to VEGF alone
(Fig. 1F–G).
3.2. SP inhibits VEGF-induced vascular permeability by preventing
dissociation of endothelial ZO-1.
To determine how the SP-mediated increase in ZO-1 expression may
inﬂuence the barrier function of MRMEC cells, we exploited an in vitro
vascular permeability assay. This approach permitted dual assessment
of endothelial cell integrity (tight junction expression of ZO-1) and
extent of vascular leakage (ﬂuorescence intensity of ﬂuorescent-posi-
tive intercellular signal) in response to SP and VEGF treatments.
When MRMEC cells monolayer were treated with VEGF (100 ng/ml,
24 h), a 6-fold increase in ﬂuorescence intensity compared to control
(untreated cells) was observed indicating increased permeability. SP
partially protected against the increased permeability through pre-
servation of the cell junction integrity demonstrated by attenuation of
ﬂuorescence intensity by 36% compared to VEGF alone (p < 0.001)
(Fig. 2A–B). Furthermore, ZO-1 immunostaining conﬁrmed the loss of
tight junction (TJ) integrity following VEGF treatment, which was
again attenuated by SP pre-treatment (Fig. 2A).
To support the in vitro data, we investigated the protective eﬀect of
SP on VEGF-induced vessel leakage in vivo. Groups of C57BL/6J mice
were treated with a single intravitreal injection of VEGF, SP, SP+VEGF
or vehicle control. Vascular leakage was measured at 48 h post-injec-
tion by extravasation of intravascular Evans Blue dye. Flat-mount ret-
inal preparations showed that intravitreal injection of VEGF induced a
70% increase in Evans blue extravasation as determined via ﬂuorescent
intensity compared to control. Intravitreal injection of SP together with
VEGF suppressed the VEGF-induced leakage in retinal vessels by 47%.
By contrast, only minimal vascular leakage was observed in animals
receiving normal saline or SP alone (Fig. 3A–B).
Deploying ZO-1 immunoﬂuorescence staining, we assessed the
Fig. 2. Substance P inhibits VEGF-induced retinal vascular permeability in vitro. (A) Immunostaining of MRMECs for Fluorescein-streptavidin to detect permeable
areas and for ZO-1 to show cell-cell contact; cells deprived of serum for 24 h and incubated in the presence of SP (20 μM), VEGF (100 ng/ml) or SP with VEGF (pre-
incubated with SP for 6 h before addition of VEGF) for 24 h (n = 4 per group). (B) Fluorescein intensity associated with DAPI expression was calculated by Image J in
all treatment groups. Scale bar, 200 μm. Data represents means ± SD of relative values vs control from 3 independent experiments. *P < 0.05; **P < 0.01;
***P < 0.001, statistical analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons.
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spatial relationship between TJ protein expression and changes in
paracellular vascular permeability. Classical staining of intact vascu-
lature exposes the demarcated lateral membranes of retinal micro-
vascular endothelial cells. Localization and integrity of junctional
complexes were not altered following exposure to SP or saline alone.
However, intravitreal injection of VEGF resulted in a dramatic loss of
staining of the ZO-1 junctional protein network. Combined adminis-
tration of SP with VEGF led to a signiﬁcant increase in the expression of
ZO-1 protein (Fig. 3C). Collectively this data supports a protective eﬀect
of SP on retinal vascular integrity.
3.3. SP protects retinal ganglion cell against apoptotic cell death induced by
NMDA ex vivo retinal explants
Given the distribution of neurotransmitter SP expression in the
inner retina, next we wished to determine whether SP conferred a
homeostatic role and delivered a protective eﬀect leading to preserva-
tion of retinal microarchitecture and other cell types, speciﬁcally retinal
ganglion cells. Ex vivo retinal explants cultured for 2 weeks maintained
the laminar structure of the retina, with no loss of cells from the outer
and inner retinal layers (Fig. 4A). Furthermore, immunostaining de-
monstrated major cell types were preserved after 2 weeks in culture.
Brn-3a+ retinal ganglion cell (RGC) axon bundles were observed in the
retinal nerve ﬁber layer, but also GFAP+ astrocytes and Müller cells
and Rhodopsin+ photoreceptors were retained (Fig. 4B).
To evaluate the role of SP on RGC health, we employed the well-
established NMDA-induced model of excitotoxic damage in retinal ex-
plants [25]. Quantiﬁcation of TUNEL+ cells shows NMDA treatment
results in a 10-fold increase in the number of apoptotic cells. Pre-
treatment of the explant with SP for 6 h prior to NMDA exposure sig-
niﬁcantly reduced the cytotoxic eﬀects, as shown by a reduction in the
number of TUNEL+ cells by 27% compared to NMDA alone, SP
treatment alone did not lead to any apoptosis or retinal toxicity, with
comparable number of TUNEL+ cells to control explants (Fig. 4D and
E). To conﬁrm with an in vivo correlate we analyzed wholemounts
obtained from eyes exposed to NMDA for 24 h (10 nmol, intravitreal
injection) where upon following incubation with NMDA for 24 h RGC
NMDA-induced excitotoxic damage of RGC cells undergoing apoptosis
was noted. (Fig. 4C).
3.4. SP protects ganglion cells from NMDA excitotoxicity in vivo
To validate the protective eﬀect of SP in suppressing NMDA-induced
RGC apoptosis, we assessed in vivo eﬃcacy. In these experiments, in-
travitreal administration of NMDA (10 nmol) was used to induce neu-
ronal excitotoxic damage in the eyes of mice. A dose-response was
undertaken previously to ascertain the optimal dosing of SP
(10 nmol–40 nmol). We found that 20 nmol of SP demonstrated the
optimal protective eﬀect in NMDA-induced ganglion cell apoptosis
model (Supplemental Figs. 1A–B). The extent of NMDA-induced RGC
apoptosis was quantiﬁed by immuno-staining (TUNEL and Brn-3a po-
sitivity) of ex vivo retinal whole-mounts (Fig. 5A–D). We observed a
signiﬁcantly higher ﬂuorescence in the NMDA-injected eyes than PBS-
injected contralateral eyes. Combined administration of SP and NMDA,
resulted in a signiﬁcant reduction (34%) in the ﬂuorescence intensity of
TUNEL+ cells in the retina as compared to NMDA alone. Of note, no
signiﬁcant diﬀerences were detected between the SP-injected experi-
mental eyes and the respective control (Fig. 5A, C).
The number of Brn-3a+ cells was also evaluated from the retinal
ﬂat mount, and showed that NMDA reduced decreased the number of
Brn-3a+ cells to 45% of control. Conversely, after SP was injected
along with NMDA injection in the mouse vitreous, there was a statis-
tically signiﬁcant protective eﬀect as larger number of Brn-3a+ cells
remained (from 45% to 68% of control) (Fig. 5B, D).
4. Discussion
In this study, we demonstrated a protective role of SP against
NMDA-induced retinal ganglion cell death in vitro and in vivo.
Furthermore, our results revealed that SP suppresses VEGF-induced
increase in vascular permeability. These ﬁndings suggest that mod-
ulating SP levels can be a potential new avenue of treatments to
Fig. 3. Substance P prevents vascular leakage in the mouse retina. Groups of C57BL/6J mice received intravitreal injections of SP (20 nmol), VEGF (100 ng), SP
in combination with VEGF or vehicle control (n = 6 per group). (A) Representative images 48 h following treatment demonstrate diﬀerences in the vasculature
(leakage of Evans blue dye, which appears as red). Scale bar = 50 μm. (B) The ﬂuorescent intensity of Evans blue was quantiﬁed by Image J. (C) Representative
confocal images of retinal vessels immunostained with ZO-1. Scale bar = 20 μm. Data represents means ± SD of relative values vs control from 3 independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001, statistical analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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preserve the neurovascular unit in retinal neurodegenerative and vas-
cular diseases.
Regulation of vascular permeability plays a major role in the pa-
thophysiology of neovascular diseases, with numerous VEGF-inhibitory
strategies to reduce retinal vascular permeability [26]. The integrity of
endothelial cell–cell junctions and vascular barrier function is regulated
by a series of adhesion molecules that form three types of junctions,
tight, gap and adherens [27,28,29]. Among the various protein com-
ponents of tight junctions, ZO-1 is a phosphoprotein that participates in
multiple protein–protein interactions and has been implicated in the
regulation of tight junction integrity [30,31,32]. Furthermore, VEGF
disrupts tight junctions by altering phosphorylation of ZO-1 and oc-
cludin through a Src-dependent pathway [33,34]. In our experiments,
and in agreement with previous studies, we were also able to demon-
strate the inhibitory eﬀect of VEGF on the expression of tight junction
protein ZO-1 in endothelial cells. However here, we demonstrated that
VEGF and SP have opposite eﬀects on the expression of ZO-1 in the
MRMEC monolayers. SP increased ZO-1 expression, which supported
our initial hypothesis that SP maintains the vascular integrity.
To further assess the mechanism of action of SP, we assessed
vascular permeability both in vitro and in vivo. We observed that SP can
attenuate VEGF-induced vascular leakage of microvascular retinal en-
dothelial cell monolayer. These results suggest that SP improves barrier
function to maintain homeostasis of retinal endothelial cells. Our re-
sults support other data demonstrating that SP up-regulates the tight-
junction protein ZO-1 in various cell types, including epithelial cells
[35], and also promotes wound healing and tissue integrity [36,37].
During pathological conditions, many components may interplay to
determine either death or survival of RGCs [11], but there are many
mechanisms for RGC death that are shared among diﬀerent diseases
[38]. Changes in electrical activity [39] and growth factor deprivation
[40] likely contribute to RGC death after optic nerve injury, while other
mechanisms, such as excitotoxicity [41], ischemia and hypoxia [7],
oxidative stress [42] and abnormal protein traﬃcking, induce RGC
death. Xie's [14] results from studies in diabetic rats showed that the
levels of SP in the retina and serum were signiﬁcantly reduced, with an
associated increase in apoptosis and caspase-3 activity in the retina.
More importantly, restoration of endogenous SP paralleled the inhibi-
tion of the apoptosis of the RGC and the caspase-3 activity in the dia-
betic animals. This indicates its potential use in the development of
Fig. 4. Substance P protects against apoptotic cell death in the retinal explants induced by NMDA. Gross morphology and tissue viability of rat retinal explants,
cultured in B27/N2 and maintained to Day 14. (A) Wholemount photographs. Scale bar, 2 mm. Sectioned explants, stained with DAPI to visualize nuclei, de-
monstrated good survival of cells in the ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL). Scale bar, 200 μm. (B) Immuno-staining of
retinal sections from day 14 explant for diﬀerent cell markers (Rhodopsin, Brn-3a, GFAP), counterstained with DAPI (blue). Scale bar, 200 μm. (D, E) Representative
images showing TUNEL-positive cells in rat explants exposed to NMDA (10 μM), SP (20 μM) or pretreated with SP 6 h before NMDA exposure (n = 6 per group). Scale
bar, 100 μm. Quantiﬁcation of TUNEL positive cells expressed as percentage of control. (C) Representative images of retinal wholemount obtained from eyes exposed
to NMDA for 24 h (10 nmol, intravitreal injection), showing TUNEL+ (red), Brn-3a+ (green), and cell nuclei stained with DAPI (blue). 3D image indicates NMDA
speciﬁcally induced TUNEL+ in GCL. Scale bar, 50 μm. Data represents means ± SD of relative values vs control from 3 independent experiments. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001, statistical analysis was performed with one-way ANOVA with Dunn's test for multiple comparisons. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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therapeutic strategies to ﬁght retinal disease.
Here we extend the known beneﬁcial eﬀect to show that SP exerts
neuroprotective properties on RGC in NMDA-induced neuro-ex-
citotoxicity apoptotic cell death both in vitro and in an animal model.
For SP neuroprotective property we speculated that SP exerts its pro-
tective function mainly through MAPK signaling, as MAPK has been
shown to regulate tight junction function. In other tissues, p38 MAPK is
activated by tumor necrosis factor α and interferon γ, leading to down-
regulation of occludin, ZO-1 and claudin-2, which contributes to the
increase in paracellular permeability [43]. In our experiments, we si-
milarly found that both phosphorylated forms of MAPK (p38 and p44/
42) were reduced upon SP treatment, alongside ZO-1 upregulation,
supporting that SP inactivated MAPK to maintain vascular integrity.
Furthermore, several cytokines such as IL-10 and IL-12 have been ob-
served to mediate partially the eﬀect of SP in several organs/tissues
[44,45]. There appear to be opposing data on the role of SP on en-
dothelial cells. For example, SP has been reported to regulate angio-
genesis directly by inducing endothelial cells to produce nitric oxide
[46], or indirectly via its interactions with mast cells and granulocytes
[47], while VEGF blockade does not abolish the proangiogenic property
of SP [48]. On the other side, in support of our ﬁndings, SP can re-
portedly prevent laser-induced retinal degeneration in vivo, by
suppressing inﬂammation and reducing neovascularisation [49]. These
diﬀerences are likely attributable to diﬀerent animal models studied,
the type and kinetics of retinal insult, selective mechanisms potentially
aﬀecting only some subtypes of RGC or experimental methods that
select some types of RGC for observation over others (e.g. central retina
versus peripheral) [11]. Nevertheless, as we continue to decode the
molecular mechanisms of SP, other important potential therapies may
be incorporated into a multifaceted approach. It will be important
moving forward to transition as many of these are possible into well-
structured clinical trials in humans.
In conclusion, we have shown that SP is neuroprotective, suppres-
sing apoptosis of retinal ganglion cells induced by NMDA, and SP also
protects against VEGF-induced microvascular leakage. Both eﬀects de-
monstrate the signiﬁcant role that the neuropeptide transmitter plays in
maintaining neurovascular unit homeostasis.
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Fig. 5. Substance P protects neuronal cell death induced by NMDA in murine retina. Representative images of retinal whole-mounts prepared for TUNEL assay
(A) and Brn-3a immunostaining (n = 6 per group). (B) 24 h following a single intravitreal injection of SP (20 nmol), NMDA (10 nmol), SP combined NMDA or vehicle
control (n = 6 per group). (C) The ﬂuorescence intensity of TUNEL+ was quantiﬁed by Image J, showing that SP decreases the intensity of apoptotic retinal ganglion
cells induced by NMDA. (D) Brn-3a+ were counted by Image J, showing that SP protects against the loss of retinal ganglion cells. Data represents means ± SD of
relative values vs control from 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, statistical analysis was performed with one-
way ANOVA with Dunn's test for multiple comparisons.
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